2023
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Ahmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.Peer-Reviewed Original ResearchDermatologic toxicitiesSOC patientsBreast cancerEducational interventionFurther multi-institutional studiesCancer treatmentMulti-institutional studyAfrican American/BlackDermatologic effectsInfusion centerAmerican/BlackPatient educationMinority patientsColor patientsEducational pamphletChemotherapyPatientsLarger sample sizeMedical careSkin typePilot studyHigh school degreeSmall sample sizeSample sizeMost participants
2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.Peer-Reviewed Original ResearchConceptsCutaneous adverse eventsCancer patientsAnticancer treatmentEvidence-based algorithmNumber of patientsQuality of studiesAdverse eventsOncology patientsPatients' qualityPatient outcomesSun protection productsSurvivors' qualitySkincare regimenCounter agentsSkin conditionsPatientsHealthcare providersHealthy skinMultidisciplinary teamCancer treatmentAdvanced providersGeneral measuresTreatmentDelphi approachSkincare formulations
2020
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelines